



**CHINA HEALTH GROUP INC.**

**中國醫療集團有限公司**

(Carrying on business in Hong Kong as “萬全醫療集團”)

*(Formerly known as “Venturepharm Laboratories Limited”)*

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 08225)

**INTERIM REPORT 2017  
FOR THE SIX MONTHS ENDED 30 JUNE 2017**

*\*for identification only*

INTERIM REPORT 2017  
FOR THE SIX MONTHS ENDED 30 JUNE 2017

***Characteristics of the Growth Enterprise Market (the “GEM”) of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”)***

***GEM has been positioned as a market designed to accommodate companies to which a high investment risk may be attached than other companies listed on the Stock Exchange. Prospective investor should be aware of the potential risk of investing in such companies and should make the decision to invest only after due and careful consideration. The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and other sophisticated investors.***

***Given the emerging nature of companies listed on GEM, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM.***

*The Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This report, for which the directors (the “Directors”) of China Health Group Inc.(the “Company”) collectively and individually accept responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of the Stock Exchange for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquires, confirm that, to the best of their knowledge and belief: (1) the information contained in this report is accurate and complete in all material respects and not misleading; (2) there are no other matters the omission of which would make any statement in this report misleading; and (3) all opinions expressed in this report have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.*



## CHINA HEALTH GROUP INC.

### 中國醫療集團有限公司

(Carrying on business in Hong Kong as “萬全醫療集團”)

*(Formerly known as “Venturepharm Laboratories Limited”)*

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 08225)

The Directors are pleased to announce the unaudited interim report of the Company and its subsidiaries (the “Group”) for the six months ended 30 June 2017, together with the comparative figures.

#### HIGHLIGHTS

1. The Group achieved a turnover of about RMB 16,100,000 for the six months ended 30 June 2017, representing an increase of approximately 3% compared with that of the corresponding period in 2016.
2. The Group achieved profit before taxation of about RMB 4,933,000 for the six months ended 30 June 2017, representing an increase of approximately 7% compared with that of the corresponding period in 2016.
3. The Group achieved net profit of about RMB 4,193,000 for the six months ended 30 June 2017, representing an increase of approximately 7% compared with that of the corresponding period in 2016.
4. Earnings per share (basic) amounted to RMB 0.42 cent for the six months ended 30 June 2017, representing a decrease of approximately 2% compared with that of the corresponding period in 2016.

## CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

	Notes	Unaudited		Unaudited	
		Three months ended 30 June		Six months ended 30 June	
		2017	2016	2017	2016
		RMB'000	RMB'000	RMB'000	RMB'000
Turnover	2	7,812	8,950	16,100	15,624
Cost of sales		<u>(2,409)</u>	<u>(3,276)</u>	<u>(3,723)</u>	<u>(3,750)</u>
<b>Gross profit</b>		<b>5,403</b>	<b>5,674</b>	<b>12,377</b>	<b>11,874</b>
Other income		12	208	15	223
Administrative expenses	3	<u>(2,926)</u>	<u>(2,450)</u>	<u>(7,406)</u>	<u>(6,987)</u>
<b>Profit from operations</b>		<b>2,489</b>	<b>3,432</b>	<b>4,986</b>	<b>5,110</b>
Finance costs		<u>(30)</u>	<u>(356)</u>	<u>(53)</u>	<u>(496)</u>
<b>Profit before taxation</b>		<b>2,459</b>	<b>3,076</b>	<b>4,933</b>	<b>4,614</b>
Income tax	6	<u>(369)</u>	<u>(684)</u>	<u>(740)</u>	<u>(692)</u>
<b>Profit for the year</b>		<u><b>2,090</b></u>	<u><b>2,392</b></u>	<u><b>4,193</b></u>	<u><b>3,922</b></u>
Attributable to :		<b>0</b>		<b>0</b>	
equity holders of the Company		<b>2,090</b>	<b>2,392</b>	<b>4,193</b>	<b>3,922</b>
Minority interests		<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
Profit for the year		<u><b>2,090</b></u>	<u><b>2,392</b></u>	<u><b>4,193</b></u>	<u><b>3,922</b></u>
<b>Earnings per share (cent)</b>		<b>0</b>			
- basic	5	<b>0.21</b>	<b>0.26</b>	<b>0.42</b>	<b>0.43</b>
- diluted	5	<b>0.21</b>	<b>0.23</b>	<b>0.41</b>	<b>0.39</b>

## CONSOLIDATED BALANCE SHEET

	Notes	Unaudited 30 June 2017 RMB'000	audited 31 Dec 2016 RMB'000
<b>Non-current assets</b>			
Property, plant and equipment		3,259	3,771
		<u>3,259</u>	<u>3,771</u>
<b>Current assets</b>			
Work-in-progress		2,607	2,086
Trade receivables and notes receivables		8,245	551
Other receivables, deposits and prepayments		6,428	4,683
Cash and cash equivalents		894	1,753
		<u>18,174</u>	<u>9,073</u>
<b>Current liabilities</b>			
Short term loan	7	1,500	1,500
Trade and other payables		29,358	23,311
Receipt in advance		2,274	4,855
Loan from related companies		8,321	8,321
Derivative financial liabilities			
tax liabilities		954	24
		<u>42,407</u>	<u>38,011</u>
<b>Net current assets</b>		<u>(24,233)</u>	<u>(28,938)</u>
<b>Total assets less current liabilities</b>		<u>(20,974)</u>	<u>(25,167)</u>
<b>Non-current liabilities</b>			
		-	
<b>Net assets</b>		<u>(20,974)</u>	<u>(25,167)</u>
<b>Capital and reserves</b>			
Share capital		88,673	88,673
Reserves		(109,647)	(113,840)
Total equity attributable to equity shareholders of the Company			
<b>Minority interests</b>		-	-
<b>Total equity</b>		<u>(20,974)</u>	<u>(25,167)</u>

## CONSOLIDATED CASH FLOW STATEMENT

---

	Unaudited six months ended 30 June	
	2017	2016
	RMB'000	RMB'000
Net cash used in operating activities	(819)	(5,920)
Net cash used in investing activities	-	-
Net cash used in financing activities	(40)	(38)
Net decrease in cash and cash equivalents	(859)	(5,958)
Cash and cash equivalents at beginning of the period	<u>1,753</u>	<u>6,775</u>
Cash and cash equivalents at end of the period	<u><u>894</u></u>	<u><u>817</u></u>

## CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

	Share- Based		Special Reserve	Capital reserve	Statutory reserve	Statutory enterprise		Minority interest	Total
	Share capital	Payment reserve				fund expansion	Retained earnings		
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
At 1 January 2016	81,699	5,626	6,039	2,254	3,821	6,986	(146,093)	-	(39,668)
New issue of shares	-	-	-	-	-	-	-	-	-
Loss for the period	-	927	-	-	-	-	3,922	-	4,849
At 30 June 2016	<u>81,699</u>	<u>6,653</u>	<u>6,039</u>	<u>2,254</u>	<u>3,821</u>	<u>6,986</u>	<u>(142,171)</u>	<u>-</u>	<u>(34,819)</u>
At 1 January 2017	88,673	7,050	6,039	6,231	3,821	6,986	(143,966)	-	(25,166)
New issue of shares									
Profit for the period							4,193		4,193
At 30 June 2017	<u>88,673</u>	<u>7,050</u>	<u>6,039</u>	<u>6,231</u>	<u>3,821</u>	<u>6,986</u>	<u>(139,773)</u>	<u>-</u>	<u>(20,973)</u>

## NOTES TO THE FINANCIAL STATEMENTS

### 1. Accounting policies and basis of preparation

The unaudited condensed financial statements have been prepared in accordance with Hong Kong Financial Reporting Standards (HKFRSs) HKAS 34 Interim Financial Reporting. In addition, the financial statements comply with the applicable disclosure provisions of Rule 18, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The accounting policies adopted are consistent with those followed in the preparation of the Group's audited consolidated financial statements for the year ended 31 December 2016.

### 2. Turnover and revenue

The Group is principally engaged in integrated services which including Clinical Research Service (CRS), Regulatory Affair Service (RAS) and Post Market Service (PMS). Breakdown of the revenue from all services is as follows:

	Unaudited three months ended 30 June		Unaudited six months ended 30 June	
	2017	2016	2017	2016
	RMB'000	RMB'000	RMB'000	RMB'000
Contracted clinical research services (CRS)	2,377	7,576	4,671	13,255
Post Market Service (PMS)	5,435	1,374	11,429	2,369
Other Service				
	<u>7,812</u>	<u>8,950</u>	<u>16,100</u>	<u>15,624</u>

### 3. Administrative expenses

	Unaudited Three months ended 30 June		Unaudited Six months ended 30 June	
	2017	2016	2017	2016
	RMB'000	RMB'000	RMB'000	RMB'000



## Administrative expenses

<b>2,926</b>	<b>2,450</b>	<b>7,406</b>	<b>6,987</b>
--------------	--------------	--------------	--------------

Administrative expenses for the six months ended 30 June 2017 increased by 6% compared with that of the corresponding period in 2016 mainly because of the increase of personnel costs.

### 4. Dividends

The board does not recommend the payment of any interim dividend for the six months ended 30 JUNE 2017 (2016: Nil).

### 5. Earnings per share

Basic earnings per share for the three months ended 30 June 2017 is calculated by dividing the unaudited profit attributable to owner of the Group for the period, approximately RMB 4,193,000 (approximately profit of RMB 3,922,000 for the corresponding period of 2016) by the weighted average number of 992,771,660 ordinary shares (2016: 915,271,660 shares) for the period.

The calculation of the diluted earnings per share the three months ended 30 June 2017 is based on the unaudited earnings attributable to owner of the Group and adjusted to eliminate the interest expense less the tax effect for the period. The weighted average number of 1,013,070,460 (2016: 1,017,869,360) ordinary shares is adjusted for the effect of the dilutive potential ordinary shares to be issued to the exercise of the options granted under all relevant Share Option Schemes and the conversion of convertible bond of 20,298,800 (2016: 102,597,700) shares for the period .

### 6. Income Taxes

No Hong Kong profit taxes has been provided for, as the Group had no estimated assessable profits in Hong Kong for the period(2016: Nil).

PRC Enterprise Income Tax has been calculated on the estimated assessable profit for the year according to the relevant laws and regulations. The applicable income tax rate is ranging from 15% to 25% as at 31 June 2017 (2016: 15%-25%). During the year, Beijing Venturepharm Sunshine Pharmaceutical Technology Co, Ltd.北京萬全陽光醫學技術有限公司) and Hainan Shengke Life Science Research Co, Ltd.(海南盛科生命科學研究院) have obtained the qualification for High-tech Enterprises and are subject to the PRC Enterprise Income Tax at 15%.

<b>Unaudited</b>	<b>Unaudited</b>
<b>three months</b>	<b>Six months</b>
<b>Ended 30 June</b>	<b>ended 30 June</b>

	<b>2017</b>	2016	<b>2017</b>	2016
	<b>RMB'000</b>	RMB'000	<b>RMB'000</b>	RMB'000
Chinese Income Tax	<b>369</b>	<b>684</b>	<b>740</b>	<b>692</b>

## 7. Borrowings

	<b>Unaudited</b>	
	<b>Six months ended 30 June</b>	
	<b>2017</b>	2016
	<b>RMB'000</b>	RMB'000
Bank Loan	<b>1,500</b>	<b>1,500</b>
Convertible bond		<b>6,237</b>
	<b>1,500</b>	<b>7,737</b>

## 8. Segment information

As all assets and operations of the group are located in China during this period, there is no geographical segment analysis.

## **MANAGEMENT DISCUSSION AND ANALYSIS**

### **FINANCIAL REVIEW**

The Group has achieved a turnover of about RMB 16,100,000 for the six months ended 30 June 2017, representing an increase of approximately 3% compared with that of the corresponding period in 2016, which is mainly due to the turnover increase in Post Market Service.

### **PROSPECTS**

The Group will focus on the advantages of resources to improve its capacities and performance in services by providing fully integrated pharmaceutical services which including Clinical Research Service (CRS), Regulatory Affair Service (RAS) and Post Market Service (PMS). In the meantime, the Group believes that as the Government further standardizes and implements its supervision, the market environment will become more favorable to the Group. Meanwhile, the investment from Chinese Government into the scientific research of biologic and pharmaceutical technology will greatly stimulate the R&D service market. The upcoming new booming age of the pharmaceutical industry will not only present the Group with rare and precious business opportunities, but also considerable return for the shareholders.

### **DIVIDEND**

The Directors have not recommended payment of any interim dividend for the six months ended 30 June 2017.

### **SIGNIFICANT INVESTMENTS**

Nil

### **CONTINGENT LIABILITIES**

As of 30 June 2017, the Group did not have any contingent liabilities not recorded.

### **FUTURE PLANS FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS**

Other than those disclosed in the Company's public announcements, the Group does not have any other plans for material investments or capital assets.

## **FOREIGN EXCHANGE EXPOSURE**

During the period under review, the Group's transactions were substantially denominated in Renminbi ("RMB"). The Group closely monitors its foreign currency risk from time to time and will use appropriate hedging when necessary.

## **PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S SHARES**

Neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed shares during the six months ended 30 June 2017.

## **COMPETING INTERESTS**

As of 30 June 2017 none of the Directors or the management shareholders of the Company and their respective associates (as defined in the GEM Listing Rules) had any interest in a business that competes or may compete with the business of the Group.

## **CORPORATE GOVERNANCE**

### **(1) Corporate governance practices**

The Company applied the principles and fully complied with the Code Provision as set out in Appendix 15 of the GEM Listing Rules (“CG Code”) with certain deviations save as disclosed in respect of the roles of chairman and chief executive officer.

### **(2) Directors’ securities transactions**

The Company has adopted the Company Code for Securities Transactions by Directors of Listed Issuers in compliance with the provisions that are set out in the GEM Listing Rules as its own code of conduct for Directors’ dealings of securities since 29 June 2005. Specific enquiries have been made with all Directors and the Directors confirmed that they have complied with the required standard set out in the Company Code in the period from 1 January 2017 to 30 June 2017.

### **(3) Chairman and chief executive officer**

Chairman of the Board is responsible for the leadership and effective running of the Board, and ensures that all key and appropriate issues are discussed by the Board in a timely and constructive manner.

However, the Chief Executive of the Company has not yet been appointed. Currently, the day-to-day management of the Company’s business is handled by the executive directors and senior management, who take the responsibility to run the Group’s business and to implement the Group’s strategy so as to achieve the overall commercial objectives of the Company.

### **(4) Board practice and procedures**

During the period from the date of listing to 30 June 2017, the Company has been in compliance with the board practices and procedures as set out in Rule 5.34 of the GEM Listing Rules.

### **(5) Audit committee**

The audit committee was established with written terms of reference in compliance with the GEM Listing Rules. The primary duties of the audit committee are to review the Company’s annual reports and accounts, half-yearly reports and quarterly reports and internal control system of the Group and provide advice and comments to the Board. The audit committee has three members comprising the three Independent Non-executive Directors, Dr. Shou Yuan WU, Dr. Bin Hui NI and Mr. Mark Gavin Lotter. Dr. Shou Yuan WU is the chairman of the audit committee.

The company’s financial statements for the six months ended 30 June 2017 have been reviewed by the audit committee.

**(6) Directors' Acknowledgement of Their Responsibility for the Financial Statements**

The Directors acknowledge that they take full responsibility in the preparation of the financial statements.

***By Order of the Board***

China Health Group Inc.

William Xia GUO

***Chairman***

Hong Kong, 13 August, 2017

*As at the date of this announcement, the Board comprises:*

*Executive Directors:*

William Xia GUO

Maria Xue Mei SONG

*Non-Executive Directors:*

Michael SU

*Independent Non-Executive Directors:*

Shou Yuan WU

Bin Hui NI

Mark Gavin Lotter